Cambiotics, a pioneering biotech company developing next-generation precision health solutions, has successfully closed a Seed investment round of EUR ~4 million with an international consortium, led by the investor Collaborative Fund, with participation from EIFO (Danish Export and Investment Fund), and True, as co-investors.
Cambiotics’ approach builds on world-class research from the Patil lab at the MRC Toxicology Unit, University of Cambridge. Professor Kiran Patil and Dr Anna Lindell, co-founders of Cambiotics, identified that certain species of gut bacteria can take in and store per- and polyfluoroalkyl substances (PFAS), a group of toxic pollutants commonly known as ‘forever chemicals’. Storage of PFAS by bacteria allowed their natural excretion from the body in mice. Their findings were published last year in Nature Microbiology.
The funding will enable Cambiotics to advance its scientific and clinical roadmap in 2026, including the initiation of its first human clinical trial in the United States and preparations for the US launch of its debut product, 46&, later this year. Initial market focus will be on groups with elevated exposure risk to PFAS, including firefighters, as well as early adopters in the biohacker and health-optimization community. Anyone interested can sign up for their waiting list.
PFAS are widespread throughout our environment, are detectable in most people worldwide, and are linked to a range of adverse health outcomes. While regulatory efforts and public awareness around PFAS continue to grow, there are limited options available to address the PFAS levels already present in the human body.
Cambiotics is a pioneering biotech company dedicated to help reduce levels of PFAS by developing next-generation probiotic solutions. Cambiotics was founded in 2024 with support from Denmark’s BioInnovation Institute and Cambridge Enterprise, the innovation arm of the University of Cambridge. The company is also working to provide early access for high-risk groups such as firefighters and military personnel.
Peter Holme Jensen, CEO of Cambiotics, expressed his enthusiasm for the funding’s potential: “The partnership with Collaborative Fund, EIFO, and True that this funding represents, also marks the next phase of Cambiotics development, where focus will be on upscaling of products, clinical validation, and first launch of product in the US market.”
The Patil group aims to discover and model complex (xeno-) metabolic networks emerging in the gut microbiota and thereby gain mechanistic insights into microbiome-mediated toxicity. Their interdisciplinary programme brings together computational and experimental approaches. The Patil group’s work has brought forward the fundamental role of our gut microbiota in determining drug efficacy and modulating the toxic effects of common chemical pollutants such as PFAS.
Professor Kiran Patil, MRC Toxicology Unit investigator, shared how important this is for translating research findings: “This timely investment will enable Cambiotics to test its innovative probiotic in a clinical setting. We are excited to see our basic science discovery getting a step closer to removing PFAS 'forever chemicals' from the human body.”
Matt Kaufman, investor at Collaborative Fund, highlighted the broader impact of the investment: “PFAS exposure is a massive and growing problem. These chemicals are everywhere; they stay in the body for years, and nearly everyone already carries a measurable burden. As research continues, it’s becoming increasingly clear that PFAS are linked to a wide range of negative health outcomes. Today, there are no practical ways to remove them. Cambiotics is one of the first companies building a real path to removing PFAS from the body, and we couldn’t be more excited to be backing them.”